METHOD OF DETERMINATION OF ATHEROGENICITY OF IMMUNE COMPLEXES Russian patent published in 2015 - IPC G01N33/49 G01N33/539 G01N33/92 

FIELD: biotechnologies.

SUBSTANCE: invention can be used for determination of atherogenicity of immune complexes containing multiply modified low density lipoproteins (IC-MMLDLP). For this purpose basic calcium superphosphate of IC-MMLDLP is prepared from human blood serum by treatment with the buffer containing 10% solution of polyethyleneglycol with a molecular weight 3350 (PEG-3350), in the ratio 1:2.5, then it is incubate within 10 minutes at a room temperature. IC-MMLDLP aggregates are pelleted, dissolved in the buffer without PEG-3350, analysed for the content of cholesterol in immune complexes (ChIK) and the level of guinea pig complement binding (EBC) by precipitated immune complexes. IC-MMLDLP atherogenicity is calculated as SSK to HIK ratio. If the value is below 24 units a high blood atherogenicity because of the reduced complement activating IgG function in IC-MMLDLP is stated.

EFFECT: method allows to assess IC-MMLDLP atherogenicity, diagnose atherosclerosis at a preclinical stage, and also to predict both the course of atherosclerotic process at individuals, and efficiency of the conducted therapy.

1 tbl